TUMOR NECROSIS AS A CORRELATE FOR RESPONSE IN SUBGROUP OF PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) TREATED WITH SORAFENIB

被引：0
|
作者：
Abou-Alfa, G. K. [1 ]
Zhao, B. [1 ]
Capanu, M. [1 ]
Guo, P. [1 ]
Liu, F. [1 ]
Jacobs, G. [1 ]
Gansukh, B. [1 ]
Moscovici, M. [2 ]
Lentini, G. [3 ]
Schwartz, L. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Bayer SpA PH, Med, Milan, Italy
[3] Bayer Vital GmbH, Gi Oncol, Leverkusen, Germany
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：178 / 178
页数：1
相关论文
共 50 条
  • [41] SKIN TOXICITY AS A PREDICTIVE FACTOR FOR TUMOR CONTROL IN ADVANCED HCC PATIENTS TREATED WITH SORAFENIB
    Vincenzi, B.
    Santini, D.
    Frezza, A.
    Montella, L.
    Addeo, R.
    Del Prete, S.
    Tonini, G.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S302 - S302
  • [42] SORAFENIB FOR ADVANCED HEPATOCELLULAR CARCINOMA (HCC): IMPACT OF RATIONING IN THE UNITED KINGDOM
    Smith, A.
    Hussain, S.
    Hull, D.
    Johnson, P.
    Palmer, D.
    ANNALS OF ONCOLOGY, 2010, 21 : 95 - 95
  • [43] Sorafenib for advanced hepatocellular carcinoma (HCC): Impact of rationing in the United Kingdom
    Palmer, D. H.
    Hussain, S. A.
    Smith, A. J.
    Hull, D.
    Johnson, P. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [44] A phase II study of bavituximab and sorafenib in advanced hepatocellular carcinoma (HCC).
    Yopp, Adam Charles
    Singal, Amit G.
    Arriaga, Yull Edwin
    Verma, Udit N.
    Shan, Joseph
    Kallinteris, Nikoletta
    Beg, Muhammad Shaalan
    Mansour, John C.
    Zhu, Hao
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [45] Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom
    D H Palmer
    S A Hussain
    A J Smith
    S Hargreaves
    Y T Ma
    D Hull
    P J Johnson
    P J Ross
    British Journal of Cancer, 2013, 109 : 888 - 890
  • [46] Advanced hepatocellular carcinoma treated by a combination of sorafenib and radiotherapy
    Yang, Bi-Ling
    Yeh, Chun
    Hsu, Chung-Te
    Chang, Tien-Yu
    Wang, Chung-Yih
    ADVANCES IN DIGESTIVE MEDICINE, 2014, 1 (01) : 25 - 29
  • [47] Objective response (OR) by mRECIST to predict overall survival (OS) in patients with hepatocellular carcinoma (HCC) treated with sorafenib in the SILIUS trial
    Kudo, Masatoshi
    Ueshima, Kazuomi
    Ogawa, Chikara
    Chiba, Yasutaka
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [48] PET-MR can predict survival and response in advanced hepatocellular carcinoma patients treated with sorafenib
    Hwang, Jae-Pil
    Lim, Ilhan
    Han, Chul Ju
    Park, Su Cheol
    Kim, Young Han
    Park, Joon Yeun
    Kim, Kyeong Min
    Kim, Byung Il
    Choi, Chang Woon
    Lim, Sang Moo
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [49] Early alpha-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib
    Lee, Sangheun
    Kim, Beom Kyung
    Kim, Seung Up
    Park, Jun Yong
    Kim, Do Young
    Ahn, Sang Hoon
    Han, Kwang-Hyub
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2015, 2 : 39 - +
  • [50] Diarrhea Predicts a Positive Response to Sorafenib in Patients With Advanced Hepatocellular Carcinoma
    Bettinger, Dominik
    Schultheiss, Michael
    Knuppel, Eva
    Thimme, Robert
    Blum, Hubert E.
    Spangenberg, Hans Christian
    HEPATOLOGY, 2012, 56 (02)
12345